KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | MicrobiomeTrials
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2019-12-19Est. Completion: 2032-02-13
Enrollment target: 450 participants
Locations
Banner MD Anderson Cancer Center ( Site 0001), Gilbert, Arizona, United States
City of Hope ( Site 0014), Duarte, California, United States
UCSF Medical Center at Mission Bay ( Site 0007), San Francisco, California, United States
Georgetown University ( Site 0036), Washington D.C., District of Columbia, United States
University of Kentucky Markey Cancer Center ( Site 0019), Lexington, Kentucky, United States
MedStar Franklin Square Medical Center ( Site 0033), Baltimore, Maryland, United States
Massachusetts General Hospital ( Site 0003), Boston, Massachusetts, United States
Dana Farber Cancer Institute ( Site 0002), Boston, Massachusetts, United States
Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031), Omaha, Nebraska, United States
Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon, New Hampshire, United States
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0037), Hackensack, New Jersey, United States
Laura and Isaac Perlmutter Cancer Center ( Site 0034), New York, New York, United States
Sanford Fargo Medical Center ( Site 0039), Fargo, North Dakota, United States
Other microbiome trials you might be interested in